Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Hormonal modulation of endothelial NO production Duckles SP; Miller VMPflugers Arch 2010[May]; 459 (6): 841-51Since the discovery of endothelium-derived relaxing factor and the subsequent identification of nitric oxide (NO) as the primary mediator of endothelium-dependent relaxations, research has focused on chemical and physical stimuli that modulate NO levels. Hormones represent a class of soluble, widely circulating chemical factors that impact production of NO both by rapid effects on the activity of endothelial nitric oxide synthase (eNOS) through phosphorylation of the enzyme and longer term modulation through changes in amount of eNOS protein. Hormones that increase NO production including estrogen, progesterone, insulin, and growth hormone do so through both of these common mechanisms. In contrast, some hormones, including glucocorticoids, progesterone, and prolactin, decrease NO bioavailability. Mechanisms involved include binding to repressor response elements on the eNOS gene, competing for co-regulators common to hormones with positive genomic actions, regulating eNOS co-factors, decreasing substrate for eNOS, and increasing production of oxygen-derived free radicals. Feedback regulation by the hormones themselves as well as the ability of NO to regulate hormonal release provides a second level of complexity that can also contribute to changes in NO levels. These effects on eNOS and changes in NO production may contribute to variability in risk factors, presentation of and treatment for cardiovascular disease associated with aging, pregnancy, stress, and metabolic disorders in men and women.|Androgens/physiology[MESH]|Animals[MESH]|Endothelium, Vascular/*physiology[MESH]|Estrogens/physiology[MESH]|Female[MESH]|Glucocorticoids/physiology[MESH]|Growth Hormone/physiology[MESH]|Hormones/*physiology[MESH]|Humans[MESH]|Insulin/physiology[MESH]|Male[MESH]|Nitric Oxide Synthase Type III[MESH]|Nitric Oxide/*biosynthesis[MESH]|Progesterone/physiology[MESH]|Receptor, IGF Type 1/physiology[MESH]|Receptor, Insulin/physiology[MESH]|Receptors, Estrogen/physiology[MESH]|Receptors, Glucocorticoid/physiology[MESH]|Receptors, Progesterone/physiology[MESH]|Receptors, Somatotropin/physiology[MESH] |
